Icare Finland Oy

Äyritie 22, 01510 Vantaa

Telephone +358 9 87751150

This company is co-exhibitor of
Wulff Entre Oy


Hall map

MEDICA 2016 hall map (Hall 15): stand B05

Fairground map

MEDICA 2016 fairground map: Hall 15

Our range of products

Product categories

  • 01  Electromedical equipment / Medical Technology
  • 01.04  Intense medicine / anesthesiology / respiration
  • 01.04.02  Respiration equipment
  • 01  Electromedical equipment / Medical Technology
  • 01.04  Intense medicine / anesthesiology / respiration
  • 01.04.06  Pulmonary function tests / Spirometer

Pulmonary function tests / Spirometer

Our products

Product category: Respiration equipment, Pulmonary function tests / Spirometer

Our new growth drivers concentrate on screening

Our leading market position in IOP measurement and screening provides a solid foundation for the further development of the Icare product family. With regard to Icare and IOP screening, our focus is on improving our existing products and launching new ones. 

Icare naturally continues to play a vital role in Revenio Group but, as we have stated, we are determined to make new innovative products available for the screening of diseases with significance to public health, in order to contribute to the global improvement of quality of life and life expectancy.  Their common nominators are screening, follow-up and global need for costs savings through preventive work.

In early 2015 we announced technology licensing of both asthma and skin cancer. Our objective is to launch products related to these during years to come. 

Asthma is one of the most common chronic diseases in the world. More than 300 million people suffer from it. In Finland, 9.4 % of the population has asthma. The incidence of skin cancer and its precursors is increasing rapidly throughout the world. The underlying cause of various skin changes lies in continuously increasing exposure to UV radiation. Some three million cases of skin cancer are diagnosed each year.

More Less

About us

Company details

Revenio is a Finnish health tech group operating internationally in various markets. The Group’s worldwide success is based on a Finnish invention: strongly patented IOP measurement technology. The growth of the Group’s core business is based on opening new markets for its tonometers – measuring devices intended for the measurement, monitoring, and screening of intraocular pressure as part of diagnosing glaucoma.

As the nucleus for future growth, Revenio group owns a 53 % majority share of Oscare Medical, a company that sells a device for the detection of and screening for osteoporosis, representing pioneering expertise and techno- logy in its field.

In late 2014, Revenio established a subsidiary, Revenio Research Oy, to manage the R&D projects of Revenio Group. The company will focus both on the development of existing products and on health tech-related R&D projects with the purpose of iden- tifying and commercializing new screening opportunities related to health tech. The common denominators of these projects include screening, follow-up and the global need to make cost savings in health care through preventive measures. Revenio’s goal is to build future growth paths from these nuclei alongside the current products of Revenio Group.

More Less